Nomination Committee appointed in Integrum AB (publ) ahead of the 2026 Annual General Meeting

The Nomination Committee has been formed based on the ownership structure of the Company as of January 30, 2026 (the last business day of January) and consists of the following members:

• Jakob Have, appointed by Nordic Compound Invest A/S (Chair of the Nomination Committee)
• Rickard Brånemark, appointed by Pericardium AB (also Chairman of the Board of Integrum AB)
• Kristofer Westergren, appointed by virtue of his own shareholding (Board member of Integrum AB)

The task of the Nomination Committee is to prepare and present proposals to the Annual General Meeting regarding the Chairman of the Board and other Board members, Board remuneration, auditors and auditor remuneration, and, where applicable, amendments to the instructions for the Nomination Committee.
 
Submit proposals to the Nomination Committee
Shareholders who wish to submit proposals to the Nomination Committee may do so in writing to: Integrum AB, Att: Nomination Committee, Gemenskapens gata 9, SE-431 53 Mölndal, Sweden, or by e-mail to info@integrum.se. In order for the Nomination Committee to consider submitted proposals in a constructive manner, they should be received by the Nomination Committee no later than August 21, 2026.
 
For further information, please contact:
Rickard Brånemark, Chairman of the Board
Telephone: +46 708 46 10 61
E-mail: rickard.branemark@integrum.se
 
Certified Adviser
DNB Carnegie Investment Bank AB (publ)
+46 8-588 685 70
certifiedadviser@dnbcarnegie.se
 
About us
Integrum develops and markets innovative systems for bone-anchored prostheses. Integrum's OPRA™ Implant System improves the quality of life for amputees through enhanced function, comfort and mobility. The Company's shares are traded on Nasdaq First North Growth Market.